Ginkgo Bioworks Holdings Inc (NYSE:DNA) reported Q1 sales of $80.70 million, beating the consensus of $71.68 million.
The sales declined 52%, driven by the expected ramp-down of K-12 testing in Ginkgo’s Biosecurity business unit.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased